Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877642 · ClinicalTrials.gov registry record · Phase 4
ADASUVE-Lorazepam Drug-Drug Interaction
A Phase 4 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT01877642: Completed Phase 4 study, sponsored by Alexza Pharmaceuticals.
NCT01877642 is a Phase 4 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 22 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01877642, a Phase 4 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will compare the safety and effects over time for giving both ADASUVE and lorazepam (intramuscular) compared to that of each agent given alone.
Primary Outcome
Determine the maximum level of sedation for Lorazepam 1 mg IM + ADASUVE 10 mg based on the 100 mm Visual Analog Scale (VAS) ranging from (0=sleepy to 100=wide awake)
Interventions
- DRUG Inhaled Placebo
- DRUG Inhaled loxapine 10 mg
- DRUG Lorazepam 1 mg IM
- DRUG Placebo IM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
What the finished NCT01877642 record still lists
NCT01877642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Inhaled Placebo is the first listed.
NCT01877642 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01877642 about?
NCT01877642 is a clinical study titled "ADASUVE-Lorazepam Drug-Drug Interaction". This study will compare the safety and effects over time for giving both ADASUVE and lorazepam (intramuscular) compared to that of each agent given alone.
What is the current status of trial NCT01877642?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2013-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01877642?
The interventions under investigation include: Inhaled Placebo (DRUG), Inhaled loxapine 10 mg (DRUG), Lorazepam 1 mg IM (DRUG), Placebo IM (DRUG).
Who is sponsoring clinical trial NCT01877642?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01877642's enrollment target sits among peer trials
22 1731st of 2000 higher than 259 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia